Aldosterone blockade: Current research and future trends

European Heart Journal, Supplement

Volumn 13, Issue SUPPL. B, 2011, Pages

  Bramlage, Peter ^a   Turgonyi, Eva ^b   Montalescot, Gilles ^c  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Aldosterone blocker; Atrial fibrillation; Eplerenone; Heart failure; Hypertension; Research trends

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BR 4628; CALCIUM CHANNEL BLOCKING AGENT; CANRENOIC ACID; CATION EXCHANGE RESIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FAD 286; LCL 699; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR BLOCKING AGENT; OXYGENASE INHIBITOR; PF 03882845; PLACEBO; POLYMER; RECEPTOR BLOCKING AGENT; RLY 5016; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVERSION; CONGESTIVE HEART FAILURE; DIASTOLIC HEART FAILURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; SIDE EFFECT; SYSTOLIC HEART FAILURE;

EID: 79959516061     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/sur005     Document Type: Article

References (39)

1. McManus F, McInnes GT, Connell JM. Drug insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 2008;4:44-52. (Pubitemid 350291101)
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. (Pubitemid 36384098)
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2010 Nov 14. [Epub ahead of print].
5. Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail 2009;15:68-74.
6. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Rationale and design of the aldosterone receptor blockade in diastolic heart failure trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874-882.
7. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999;353:40. (Pubitemid 29037708)
8. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-896. (Pubitemid 35434912)
9. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27: 1039-1045. (Pubitemid 26140658)
10. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248. (Pubitemid 40523144)
11. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010;31:1237-1247.
12. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-1838. (Pubitemid 37296092)
13. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026. (Pubitemid 36548598)
14. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150: 426-433. (Pubitemid 41317608)
15. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123. (Pubitemid 34840085)
16. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006;114: 2604-2610. (Pubitemid 44967343)
17. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-477.
18. Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J. Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en charge hospitaliere, lEvolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J 2009;157: 680-687.
19. Barthelemy O, Beygui F, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J, Montalescot G. Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. Am J Cardiol 2009;104:904-909.
20. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-46. (Pubitemid 32061310)
21. Beygui F, Vicaut E, Ecollan P, Machecourt J, Van Belle E, Zannad F, Montalescot G. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J 2010;160:642-648.
22. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88: 906-909, A908. (Pubitemid 32995932)
23. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK, Yu CC, Wang YC, Lai LP, Lin JL. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010;55:758-770.
24. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P, Delcayre C, Hatem SN. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005;26:2193-2199. (Pubitemid 41408006)
25. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-147. (Pubitemid 27374751)
26. Laszlo R, Bentz K, Konior A, Eick C, Schreiner B, Kettering K, Schreieck J. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. Naunyn Schmiedebergs Arch Pharmacol 2010;382:347-356.
27. Jolobe OM. Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation. Eur J Intern Med 2010;21:55.
28. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007;13:170-177. (Pubitemid 46591953)
29. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004;217:75-79. (Pubitemid 38596631)
30. Rigel DF, Fu F, Beil M, Hu CW, Liang G, Jeng AY. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther 2010;334:232-243.
31. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009;75:936-944.
32. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008;29:2171-2179.
33. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56: 831-838.
34. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285:29932-29940.
35. Montalescot G. New oral potassium binder lowers potassium levels in patients with heart failure and heart failure with chronic kidney disease. Presented at: European Society of Cardiology, Stockholm, Sweden, August 28-September 1, 2010.
36. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
37. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
38. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Fillippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909-2945.
39. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassard JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wihns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary sydromes. Eur Heart J 2007;28:1598-1660.